HOME >> MEDICINE >> NEWS
New drug holds promise to block clots in people with artery disease

DALLAS, April 30 The first study of a new drug designed to block blood clot formation showed no major adverse effects in people with stable coronary artery disease, according to a report in todays rapid access issue of Circulation: Journal of the American Heart Association.

The compound, DX-9065a, inhibits the action of factor Xa, one of the thirteen known factors involved in forming blood clots in coronary arteries. Factor Xa activates an enzyme called thrombin, which promotes the conversion of fibrinogen into fibrin, a major component of blood clots.

This is the first clinical experience with a direct, selective, reversible factor Xa inhibitor in patients with coronary artery disease, says cardiology researcher Robert A. Harrington, M.D., of the Duke Clinical Research Institute, in Durham, N.C. Our findings should lay the groundwork for further investigation of this and other agents that inhibit factor Xa in people with atherothrombosis, ischemic heart disease, and those undergoing coronary bypass surgery.

Anticoagulants, or blood-thinning drugs, work by inhibiting the ability of the blood to clot. Blood clots lodged in the coronary arteries block blood flow to the heart and cause most heart attacks. Anticoagulant therapy is commonly prescribed for people with heart disease to prevent further clot formation. The biggest drawback for anticoagulant drugs has been the potential for bleeding complications The randomized, double blind, placebo-controlled study, dubbed XaNADU, involved 73 patients with stable coronary artery disease at 10 medical centers. Their median age was 63 years, and 29 percent were women. Most had suffered a prior heart attack or had undergone angioplasty or coronary artery bypass surgery. During the study, 15 patients received a placebo, while 58 people received one of four different doses of DX-9065a, administered continuously over 72 hours.

Incidence of bleeding was minor and usually around the inf
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
29-Apr-2002


Page: 1 2

Related medicine news :

1. Chemical cousin of anti-anxiety drugs holds promise for psoriasis treatment
2. Direct payments to households in poor countries could improve maternal & child health
3. Worlds largest scientific society holds regional meeting Sept. 29 - Oct. 2 in Fort Worth
4. Case Western Reserves Flight Nursing Academy holds camp for nurses in air medical services
5. Optical glucose sensor holds promise for diabetics and intensive care patients
6. Intl Assoc for Dental Research holds 83rd General Session
7. Blood-diverting catheter holds promise for stroke treatment
8. Overweight and obesity thresholds may be misleading for Asian populations
9. Baclofen holds promise for cocaine treatment
10. Study shows combining gene therapy and radiation holds promise
11. Drug holds promise as an alternative for sickle cell patients unable to tolerate standard treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/24/2018)... ... , ... A groundbreaking ceremony will be held at 4 p.m. on Tuesday, ... Indianapolis seniors who need some help to maintain their independence. , ... all incomes. The new road is located at State Road 40 (Washington Street) and ...
(Date:9/24/2018)... ... September 24, 2018 , ... Piedmont Physicians Urology ... of Excellence. The designation recognizes that Dr. Jadick has achieved a high level ... exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or ...
(Date:9/24/2018)... ... 24, 2018 , ... Oak Street Health , a network of health ... the Little Village center to its Chicago operations. With the addition of Little Village, ... company’s vision of providing care for adults on Medicare in areas where health care ...
(Date:9/24/2018)... ... September 24, 2018 , ... Paris-based ... right to customers’ doorsteps. Its roster of talented chefs works constantly to create ... per week. In addition to its standard weekly meals, My Cuistot is happy ...
(Date:9/23/2018)... LEXINGTON, Mass. (PRWEB) , ... ... ... a management consulting firm that specializes in working with healthcare, small business ... participate in the Massachusetts Delivery System Reform Incentive Payment (DSRIP) Technical Assistance ...
Breaking Medicine News(10 mins):
(Date:9/13/2018)... , ... September 13, 2018 , ... The ultimate fitness ... at 31-57 31st St., the new arrival is called Form50 Fitness . , ... Sebastien Lagree called The Megaformer™ - a hybrid Pilates reformer with pulleys, weights, grasps ...
(Date:9/13/2018)... , ... September 13, 2018 ... ... or “Company”), a specialist pharmaceutical company focused on developing and commercializing gastrointestinal ... first candidate product. , The U.S. Food and Drug Administration (FDA) and ...
(Date:9/12/2018)... ... September 13, 2018 , ... Safety Reporting in ... 2018 — 1:30 p.m. – 3:00 p.m. ET, http://info.fdanews.com/safety-reporting-in-global-clinical-trials , Clinical ... much as fifty percent. , This can be due to a lack ...
Breaking Medicine Technology:
Cached News: